ContraFect to Present at 2nd International Symposium on Antimicrobial Hydrolytic Enzymes
November 01 2018 - 7:00AM
ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of protein and
antibody therapeutics for life-threatening, drug-resistant
infectious diseases, today announced the Company will participate
in multiple presentations at the 2nd International Symposium on
Antimicrobial Hydrolytic Enzymes (The Lysin Meeting), to be held
from November 6 – 8, 2018, in New York, NY.
ContraFect will discuss lead lysin product candidate, CF-301
(exebacase), currently being studied in a Phase 2 clinical study as
a potential novel therapy to improve clinical outcomes for patients
with Staphylococcus aureus (Staph aureus) bacteremia including
endocarditis.
“As the leading biotechnology company developing lysin
therapeutics, we are pleased to return this year to The Lysin
Meeting as both a leading sponsor and participant and to have
organized the 'Pathway from Bench to Bedside' session,” said Cara
Cassino, M.D., the Company's Executive Vice President of Research
and Development and Chief Medical Officer. “We are encouraged by
the progress of our Phase 2 study of exebacase and are excited that
upcoming data in this program will continue to be the vanguard for
our broader pipeline of lysin candidates.”
Presentation Details:
Presentation Title: Lysin CF-301 activates latent host factors
in human blood to potentiate bacteriolysisPresenter: Raymond
Schuch, Ph.D., the Company’s Vice President of ResearchSession
Title: Session One: Gram-Positive Lysins as TherapeuticsTime and
Date: 10:00 – 10:25 am ET, Tuesday, November 6, 2018
Presentation Title: In vivo pharmacologyPresenter: Dario Lehoux,
Ph.D., Consultant to the Company, Pre-Clinical DevelopmentSession
Title: Session Six: The Pathway from Bench to BedsideTime and Date:
10:05 – 10:25 am ET, Thursday, November 8, 2018
Presentation Title: Clinical Development – CF-301 (exebacase) –
A case studyPresenter: Cara Cassino, M.D., the Company's Executive
Vice President of Research and Development and Chief Medical
OfficerSession Title: Session Six: The Pathway from Bench to
BedsideTime and Date: 10:25 – 10:45 am ET, Thursday, November 8,
2018
About ContraFect:
ContraFect is a biotechnology company focused on discovering and
developing therapeutic protein and antibody products for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our lysin and monoclonal
antibody platforms to target conserved regions of either bacteria
or viruses (regions that are not prone to mutation). ContraFect's
initial product candidates include new agents to treat
antibiotic-resistant infections such as MRSA (Methicillin-resistant
Staph aureus) and influenza. ContraFect’s lead product candidate,
CF-301, is currently in a Phase 2 clinical trial for the treatment
of Staph aureus bacteremia, including endocarditis and is the first
lysin to enter clinical studies in the U.S. ContraFect is
also conducting research focused on the discovery of lysins to
target Gram-negative bacteria.
Forward-Looking
Statements:
This press release contains, and our officers and
representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding our ability to
discover and develop protein and antibody therapeutics for
life-threatening, drug-resistant infectious diseases, whether
CF-301 has the potential to be a novel therapy for Staph aureus
bacteremia including endocarditis, whether exebacase continues to
demonstrate encouraging preclinical and clinical data, the progress
of our Phase 2 study of exebacase, whether upcoming data in this
program will continue to be the vanguard for ContraFect’s broader
pipeline of lysin candidates, presentation details, our ability to
address life threatening infections using our therapeutic product
candidates from our lysin and monoclonal antibody platforms to
target conserved regions of either bacteria or viruses, whether our
initial product candidates can treat antibiotic-resistant
infections such as MRSA and influenza, and our ability to discover
new lysins targeting Gram-negative bacteria. Forward-looking
statements are statements that are not historical facts, nor
assurances of future performance. Instead, they are based on
ContraFect’s current beliefs, expectations and assumptions
regarding the future of its business, future plans, strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent risks, uncertainties and
changes in circumstances that are difficult to predict and many of
which are beyond ContraFect’s control, including those detailed in
ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Matthew ShinsekiStern Investor RelationsTel: 212-362-1200Email:
matthew@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024